STOCK TITAN

Insmed (INSM) Stock News, Jan-May 2022

INSM NASDAQ

Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.

Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.

Rhea-AI Summary

Insmed Incorporated (Nasdaq:INSM) reported strong Q1 2022 results, achieving 32% year-over-year growth with total revenue of $53.1 million, driven by ARIKAYCE sales of $40.8 million in the U.S. The company maintains its 2022 revenue guidance of at least 30% growth and a cash runway into 2024. Seven clinical trials are ongoing, including the Phase 3 ASPEN study for brensocatib. Despite a net loss of $94.6 million for the quarter, Insmed's financial position remains strong as it continues to invest in expansion and research initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.70%
Tags
-
Rhea-AI Summary

Insmed, a biopharmaceutical company focused on rare diseases, plans to release its Q1 2022 financial results on May 5, 2022. The management will conduct a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. Interested parties can join the call via phone or through a live webcast on the company's website. Insmed aims to transform lives with innovative therapies and is progressing in various serious unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.59%
Tags
conferences earnings date
-
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) announced on April 7, 2022, the granting of inducement awards to 20 new employees as part of NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 107,680 shares at an exercise price of $24.47 per share, which was the closing price on April 1, 2022. The options come with a 10-year term and a four-year vesting schedule. Insmed focuses on developing therapies for serious and rare diseases, with its first product approved in the US, Europe, and Japan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
Rhea-AI Summary

Insmed (Nasdaq: INSM) will present seven posters at the ATS 2022 International Conference, highlighting data on ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder. Key presentations include real-world evidence on ARIKAYCE's effectiveness in reducing hospitalizations and an analysis of the benefit-risk profile of brensocatib in bronchiectasis patients. The conference, set for May 13-18, 2022, in San Francisco, is a platform for the latest advancements in treatments for serious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
-
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to 15 new employees as a material inducement for their employment, as per NASDAQ Listing Rule 5635(c)(4). On March 1, 2022, the employees were granted options to purchase a total of 61,090 shares at an exercise price of $23.99 per share, reflecting the closing price on that date. The options have a 10-year term and a four-year vesting schedule, with 25% vesting on the first anniversary and subsequent vesting every six months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:10 a.m. ET. The live fireside chat will be accessible via the company's investor relations section on their website, with an archive available for 30 days post-event. Insmed focuses on treating serious and rare diseases and has launched a first-in-disease therapy approved in the U.S., Europe, and Japan. The company is also developing therapies for unmet needs in inflammatory diseases and rare pulmonary disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
conferences
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) reported a strong fourth quarter and full-year 2021, with total revenue reaching $56.1 million for Q4 and $188.5 million for the full year, a rise from $164.4 million in 2020. The company saw ARIKAYCE net sales of $159.5 million in the U.S. and launched the product in several European markets. However, Insmed also reported a net loss of $113 million in Q4 2021, leading to a full-year loss of $434.7 million. Despite these losses, the company expects ARIKAYCE revenues to grow by at least 30% in 2022, supported by a cash position of $766.8 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.00%
Tags
-
Rhea-AI Summary

Insmed Incorporated, a biopharmaceutical company focused on serious rare diseases, will present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 18, 2022, at 10:00 a.m. ET. The fireside chat will be available for live viewing on the company’s investor relations website and archived for 30 days post-event. Insmed’s first product targets chronic lung disease, with ongoing research into therapies for neutrophil-mediated inflammatory diseases and rare pulmonary conditions. The company is based in Bridgewater, New Jersey.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
conferences
-
Rhea-AI Summary

Insmed Incorporated announced the granting of inducement awards to 10 new employees as part of their recruitment strategy. Each employee received options to purchase a total of 74,410 shares of common stock at an exercise price of $23.71, aligning with the market closing price on February 1, 2022. The options have a 10-year term with a four-year vesting schedule. Insmed focuses on transforming lives through treatments for serious and rare diseases, and it is advancing a pipeline targeting unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
none
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) will announce its fourth quarter and full year 2021 financial results on February 17, 2022. Management will also provide a business and pipeline update during a conference call from 8:00 to 9:30 a.m. ET. Interested parties can join by calling specified numbers or via webcast on the company's website. A replay of the call will be available for a month. Insmed's mission is to improve lives with therapies for serious diseases, and it has a robust pipeline addressing unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.80%
Tags
conferences earnings date

FAQ

What is the current stock price of Insmed (INSM)?

Insmed (INSM) last closed at $141.33.

What is the market cap of Insmed (INSM)?

The market cap of Insmed (INSM) is approximately $31.0B.